Silverback Therapeutics, Inc.

Nasdaq : SBTX

Phase 1 biotech developing TLR8 agonist-antibodies for HER2/3 solid tumors.

  • Filed 10-11-2020
  • Set Terms --
  • IPO Date 04-12-2020
  • Lock Up 05-03-2021
Текущая цена
7.19 $
Текущая доходность
-65.76 %
Доходность за 1 день торгов
19.05 %
Доходность по итогам
Lock up периода
109.67 %
Рейтинг от IPO.one:
Дата IPO
04-12-2020
Объем размещения
11 500 000
Размер сделки ($M)
242
Диапазон цены
19-20 $
Цена IPO
21 $
Lock Up
05-03-2021
Год основания
2016
Головной офис
Seattle, WA
Веб сайт
Юристы
Latham & Watkins Cooley
Аудитор
EY
Андеррайтер
Goldman

Описание компании

We are a clinical-stage biopharmaceutical company with one product candidate in a Phase 1/1b clinical trial, and we are focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are applying our platform to create a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment (TME) in solid tumors to promote cancer cell killing. Our lead product candidate, SBT6050, is comprised of a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors such as certain breast, gastric and non-small cell lung cancers. SBT6050 is currently in a Phase 1/1b clinical trial in patients with advanced or metastatic HER2-expressing solid tumors. In this trial, we have observed changes in pharmacodynamic markers in the first dose cohort, and we anticipate providing an update on interim data from the Phase 1 dose-escalation cohorts in the second half of 2021